This table presents computed estimates for age-specific 5-year overall survival (%) in patients with resected colon cancer with/without 5FU-based adjuvant chemotherapy.
Age-Specific 5-Year OS Estimates With and Without FU-Based Adjuvant Chemotherapy
Results are presented as % patients still alive at 5 years with 95% confidence interval and group size.
Low grade - Age group under 50 years old
Group: < 50 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
83 - [80 - 86] |
85 - [83 - 88] |
2 |
0 nodes & T4 |
76 - [70 - 82] |
79 - [74 - 84] |
3 |
1-4 nodes & T1-2 |
75 - [69 - 81] |
83 - [79 - 87] |
8 |
1-4 nodes & T3 |
66 - [62 - 71] |
76 - [73 - 80] |
10 |
1-4 nodes & T4 |
54 - [46 - 64] |
67 - [60 - 75] |
13 |
5+ nodes & T1-2 |
53 - [44 - 65] |
67 - [59 - 76] |
14 |
5+ nodes & T3 |
40 - [33 - 49] |
56 - [49 - 63] |
16 |
5+ nodes & T4 |
26 - [18 - 39] |
42 - [32 - 54] |
16 |
Low grade - Age group 50 to 59 years old
Group: 50 to 59 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
81 - [78 - 83] |
83 - [81 - 86] |
2 |
0 nodes & T4 |
73 [67 - 79] |
76 [67 - 79] |
3 |
1-4 nodes & T1-2 |
72 [66 - 78] |
80 [76 - 85] |
8 |
1-4 nodes & T3 |
62 [58 - 66] |
73 [70 - 76] |
11 |
1-4 nodes & T4 |
49 [41 - 58] |
63 [56 - 70] |
14 |
5+ nodes & T1-2 |
48 [39 - 60] |
62 [54 - 72] |
14 |
5+ nodes & T3 |
35 [29 - 42] |
51 [45 - 57] |
16 |
5+ nodes & T4 |
21 [14 - 33] |
37 [28 - 48] |
16 |
Low grade - Age group 60 to 69 years old
Group: 60 to 69 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
79 [76 - 81] |
81 [79 - 84] |
2 |
0 nodes & T4 |
70 [64 - 77] |
74 [68 - 80] |
4 |
1-4 nodes & T1-2 |
69 [63 - 76] |
78 [74 - 83] |
9 |
1-4 nodes & T3 |
58 [55 - 62] |
70 [67 - 74] |
12 |
1-4 nodes & T4 |
45 [37 - 55] |
59 [52 - 68] |
14 |
5+ nodes & T1-2 |
44 [35 - 56] |
59 [51 - 69] |
15 |
5+ nodes & T3 |
31 [25 - 38] |
47 [41 - 54] |
16 |
5+ nodes & T4 |
18 [11 - 29] |
33 [24 - 44] |
15 |
Low grade - Age group 70 to 79 years old
Group: 70 to 79 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
77 [74 - 80] |
80 [76 - 83] |
3 |
0 nodes & T4 |
67 [61 - 75] |
71 [65 - 78] |
4 |
1-4 nodes & T1-2 |
66 [60 - 74] |
76 [71 - 82] |
10 |
1-4 nodes & T3 |
55 [51 - 60] |
68 [64 - 72] |
13 |
1-4 nodes & T4 |
42 [33 - 52] |
56 [49 - 65] |
14 |
5+ nodes & T1-2 |
41 [31 - 53] |
56 [47 - 67] |
15 |
5+ nodes & T3 |
27 [21 - 35] |
43 [37 - 51] |
16 |
5+ nodes & T4 |
15 [9 - 26] |
29 [20 - 41] |
14 |
High grade - Age group under 50 years old
Group: < 50 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
78 [74 - 82] |
81 [77 - 85] |
3 |
0 nodes & T4 |
69 [62 - 77] |
72 [66 - 80] |
3 |
1-4 nodes & T1-2 |
68 [60 - 76] |
77 [71 - 84] |
9 |
1-4 nodes & T3 |
57 [51 - 64] |
69 [64 - 75] |
12 |
1-4 nodes & T4 |
44 [33 - 55] |
58 [50 - 68] |
14 |
5+ nodes & T1-2 |
43 [32 - 57] |
58 [48 - 69] |
15 |
5+ nodes & T3 |
29 [22 - 39] |
45 [38 - 54] |
16 |
5+ nodes & T4 |
17 [10 - 29] |
31 [22 - 44] |
14 |
High grade - Age group 50 to 59 years old
Group: 50 to 59 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
75 [71 - 79] |
78 [74 - 82] |
3 |
0 nodes & T4 |
65 [58 - 73] |
69 [62 - 77] |
4 |
1-4 nodes & T1-2 |
64 [56 - 72] |
74 [68 - 81] |
10 |
1-4 nodes & T3 |
52 [47 - 58] |
65 [60 - 71] |
13 |
1-4 nodes & T4 |
38 [30 - 49] |
53 [45 - 63] |
15 |
5+ nodes & T1-2 |
37 [27 - 51] |
53 [43 - 64] |
16 |
5+ nodes & T3 |
24 [18 - 32] |
40 [33 - 48] |
16 |
5+ nodes & T4 |
12 [7 - 23] |
26 [18 - 37] |
14 |
High grade - Age group 60 to 69 years old
Group: 60 to 69 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
72 [68 - 77] |
76 [71 - 80] |
4 |
0 nodes & T4 |
62 [54 - 70] |
66 [58 - 74] |
4 |
1-4 nodes & T1-2 |
60 [52 - 70] |
72 [65 - 79] |
12 |
1-4 nodes & T3 |
48 [43 - 55] |
62 [57 - 68] |
14 |
1-4 nodes & T4 |
34 [26 - 45] |
49 [41 - 60] |
15 |
5+ nodes & T1-2 |
33 [23 - 47] |
49 [39 - 61] |
16 |
5+ nodes & T3 |
20 [15 - 28] |
36 [29 - 44] |
16 |
5+ nodes & T4 |
10 [41 - 60] |
22 [14 - 33] |
12 |
High grade - Age group 70 to 79 years old
Group: 70 to 79 |
Surgery Alone |
Surgery + Chemotherapy |
Abs. gain (%) |
|---|---|---|---|
0 nodes & T3 |
70 [65 - 75] |
73 [68 - 79] |
3 |
0 nodes & T4 |
59 [50 - 68] |
63 [55 - 72] |
4 |
1-4 nodes & T1-2 |
57 [49 - 67] |
69 [62 - 77] |
12 |
1-4 nodes & T3 |
45 [39 - 52] |
59 [53 - 65] |
14 |
1-4 nodes & T4 |
31 [22 - 42] |
46 [37 - 57] |
15 |
5+ nodes & T1-2 |
30 [20 - 44] |
45 [35 - 58] |
15 |
5+ nodes & T3 |
17 [12 - 25] |
32 [26 - 40] |
15 |
5+ nodes & T4 |
8 [4 - 17] |
19 [12 - 30] |
11 |
Note: Clinical date not available for patients aged 80 years or older.
Abbreviations
- OS: overall survival
- 5-FU: 5-fluorouracil
Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved. Gill S et al: Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol Vol.22 (10), 2004: 1797-1806.